Enobia Pharma

Alexion Pharmaceuticals (NASDAQ: ALXN) specializes in extremely rare diseases. Its only marketed drug, Soliris, currently targets paroxysmal Nocturnal Hemoglobinuria (PNH) a condition afflicting less than 10 thousand people worldwide. At an estimated annual cost of $400 thousand per patient,...